In Key 340B Patient Definition Case, Hospital Group Accuses Drugmakers of “Numerous Misstatements”

SC district court
Chief Judge R. Bryan Harwell of the U.S. District Court for the District of South Carolina has not yet decided on 340B Health's request to file an amicus brief in a key 340B patient definition case.
A national hospital group has asked a federal district court for permission “to correct numerous misstatements” that it says drug [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

Ranking GOP Senator on Key Committee Opens Investigation into 340B Hospital Revenue

Bill Cassidy
Sen. Bill Cassidy, ranking Republican on the Senate HELP Committee, does not appear to have the authority to compel hospitals to respond to his inquiry on 340B revenue.
The top Republican on an influential Senate committee has opened an investigation into how two major health systems use revenue [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Looming Government Shutdown Poses 340B Program Uncertainty, Potential Legal Proceeding Slowdown

US Capitol
Congress is unlikely to pass a 340B program overhaul in 2024 unless there is unexpected pressure from appellate court decisions or a Senate "group of 6" breakthrough, attorneys and lobbyists said.
The government agency that oversees the 340B program will retain just over half of its staff in the event of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Lilly and Novo Post 340B Refund Notices, Amgen Posts 340B Replenishment Notice

Eli Lily and Novo Nordisk
Lilly and Novo Nordisk are refunding 340B covered entities on some products due to 340B ceiling price adjustments.
Drugmakers Lilly and Novo Nordisk are giving covered entities refunds on some products due to 340B ceiling price adjustments, according [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Drug Purchases Reached $53.7 Billion in 2022, HRSA Data Show

Drug Channels Institute
Drug purchases under the 340B program totaled $53.7 billion in 2022, according to HRSA data obtained by Drug Channels.
Drug purchases under the 340B program totaled $53.7 billion in 2022, or 22.3% more than the $43.9 billion in 2021, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Providers Try a Range of Responses to Manufacturer 340B Contract Pharmacy Restrictions

Colleen Meiman
Community health centers are attempting to mitigate the adverse financial effects of manufacturer 340B contract pharmacy restrictions on their organizations, said Colleen Meiman, national policy advisor for State & Regional Associations of Community Health Centers.
Amid an increasing number of drugmaker restrictions and requirements on the use of contract pharmacies, 340B providers are trying a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Expanding 340B Eligibility Could Double Program Size, Says Report

IQVIA headquarters
An analysis from pharmaceutical research and data firm IQVIA projected the 340B program could more than double in size if patient eligibility expands.
The 340B program could more than double in size if the 340B patient definition expands, according to a recent report [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Senate Committee Rejects 340B Amendment to Bipartisan Health Bill

Bernie Sanders
Sen. Bernie Sanders, chair of the Senate HELP committee, opposed an amendment that would implement 340B hospital verification requirements.
A Senate committee rejected an effort to add new 340B hospital verification requirements as part of a sweeping healthcare funding [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

One Quarter of HRSA Provider Audits Closed with No Adverse Findings

Dept. of Health and Human Services sign and building
There were no adverse findings in nearly one quarter of provider audits conducted by HRSA, an agency within HHS.
Nearly one-quarter of the 200 provider audits planned for this year were closed by regulators with no adverse findings, they [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

GOP Scrutinizes Medicare Price Negotiations in House Subcommittee Hearing

Rep. Cathy McMorris Rodgers (R-Wash.), chair of the E&C Committee, and other Republican committee members criticized Medicare price negotiations in an oversight hearing this week.
Republicans and Democrats battled over Medicare price negotiation provisions under the Inflation Reduction Act (IRA) during a contentious Sept. 20 [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report